2025 Japan Prize Laureates Announced
TOKYO, Jan. 22, 2025 /PRNewswire/ -- The Japan Prize Foundation announced the winners of the 2025 Japan prize on January 22, 2025. Prof. Russell Dean Dupuis of the USA has been awarded the Japan Prize in the fields of Materials Sciences and Production, and Prof. Carlos M. Duarte of Spain has been awarded the Japan Prize in the fields...
Akeso Received Payment for the Development Collaboration on Tagitanlimab
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their collaboration on the development of tagitanlimab, an innovative humanized monoclonal antibody targeting PD-L1, following its recent marketing approval by China's National Medical Products Administration. In 2014, Akeso...
Hyundai ADM Unveils a “New Paradigm in Cancer Treatment” – Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks
SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug OTX-M, developed from the well-known injectable chemotherapy drug docetaxel, at the "Biotech Showcase 2025" held in San Francisco from January 13 to 15. The...
Anbio Biotechnology to Showcase Cutting-Edge Diagnostic Solutions at 2025 Medlab Middle East
DUBAI, UAE , Jan. 21, 2025 /PRNewswire/ -- Anbio Biotechnology ("Anbio"), a global leader in in-vitro diagnostic technologies, is excited to announce its participation in the 2025 Medlab Middle East exhibition, taking place from 3rd to 6th February at the Dubai World Trade Centre. The event is one of the region's largest and most important medical and laboratory equipment trade shows, bringing...
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Today, Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc. for MRG007, a Potential Best-in-Class antibody- drug conjugate ("ADC") for the treatment of Gastrointestinal ("GI") Cancers. Under the terms of the agreement, Lepu Biopharma has granted ArriVent exclusive rights to develop, manufacture...
Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025
BOSTON, Jan. 22, 2025 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from its Phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 (CLDN18.2 antibody-drug conjugate ) in patients with advanced or metastatic gastric cancer at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2025 (ASCO GI 2025)....
Thailand to Showcase Medical and Wellness Excellence at Expo 2025 Osaka, Kansai, Japan
BANGKOK, Jan. 22, 2025 /PRNewswire/ -- Thailand is set to make a grand debut at Expo 2025 Osaka, Kansai, Japan, highlighting the country's commitment to becoming one of the global leaders in medical and wellness services. In line with the Expo's theme "Designing Future Society for Our Lives," Thailand will demonstrate how its unique blend of traditional practices and advanced...
Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update
ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing. ASC30 oral tablet was generally safe and well tolerated. All adverse events (AEs) were mild (grade 1) or moderate (grade 2), and...
TAHO Pharmaceuticals Completes Pivotal Trial of TAH3311, the First Oral Dissolving Film Anticoagulant
TAIPEI, Jan. 21, 2025 /PRNewswire/ -- TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF). This trial was conducted following detailed discussions and alignment with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), marking a major milestone in the advancement of this innovative...
Virtus Fertility Centre Singapore Marks a Decade of Fertility Care
Virtus Health's first greenfield embryology and andrology facility in Asia strives to stay at the forefront of reproductive medicine through science, ongoing research, evidence-based personalized care, and accessible fertility education. SINGAPORE, Jan. 21, 2025 /PRNewswire/ -- Virtus Fertility Centre Singapore (VFCS) today celebrates its 10th anniversary, commemorating a decade of contributing research...
